ABLE, with the support of BASF Pharma Solutions, hosted a high-impact webinar focused on advanced biopharma ingredients for biologics, biosimilars, and cell & gene therapies. The session brought together experts to highlight how high-quality, consistent raw materials are critical to improving cell culture performance, process stability and final product quality. The webinar was opened by Dr. Balasubramanya S, General Manager, ABLE, and Dr. P. M. Murali, President, ABLE Council of Presidents, who set the context around India’s fast-growing biologics and biosimilars ecosystem and the need for high-quality, consistent and compliant raw materials in this highly regulated sector.

Dr. Aditi Poddar, Business & Technical Services Manager – South Asia, BASF Pharma Solutions, provided an overview of BASF’s global footprint. She highlighted BASF’s extensive pharma and biopharma portfolio, including excipients, APIs, lipid systems, solubilizers and 

biologics-grade surfactants for upstream, downstream and formulation stages. The technical core of the session was led by Dr. Nadya Morales-Cummings, Global Technical Marketing Manager – Biopharma Ingredients, BASF Pharma Solutions (USA). She addressed one of the biggest challenges in biologics manufacturing: raw-material variability, particularly in surfactants used in chemically defined cell-culture media.

The session highlighted India’s strong opportunity in biosimilars, CMOs, and emerging cell & gene therapies, as many blockbuster biologics go off-patent globally. BASF and ABLE emphasized their commitment to supporting Indian startups, manufacturers and academic institutions through Product sampling and technical support from BASF’s Mumbai lab, Collaboration on process optimization and formulation and Access to global R&D and application expertise. The webinar underscored that bioprocess performance is no longer driven by cells alone ingredients matter. With scientifically optimized surfactants, digital tools, and sustainability-driven manufacturing, BASF is helping Indian biopharma players achieve higher yields, better consistency and faster scale-up.

ABLE and BASF will continue this dialogue through future knowledge-sharing sessions, case studies and industry collaborations.